▪ Abstract Despite testing since the mid-1900s, only in the past three years have some
monoclonal antibodies provided sufficient efficacy and safety data to support regulatory
approval as cancer therapy. Adjuvant-edrecolomab monoclonal antibody was approved in
Germany after demonstration of a statistically significant 32% improvement over observation
alone in the seven-year mortality rate for patients with colorectal cancer. Similarly,
trastuzumab monoclonal antibody combined with chemotherapy prolonged the median time …